Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) - eVOLVECervical

Study identifier:D7984C00002

ClinicalTrials.gov identifier:NCT06079671

EudraCT identifier:N/A

CTIS identifier:2023-504374-38-00

Recruiting

Official Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Medical condition

Locally Advanced Cervical Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

Female

Estimated Enrollment

1000

Study type

Interventional

Age

15 Years - n/a

Date

Study Start Date: 22 Sept 2023
Estimated Primary Completion Date: 19 Feb 2027
Estimated Study Completion Date: 24 Oct 2029

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Gynecologic Oncology Group Foundation, European Network for Gynaecological Oncological Trial groups

Inclusion and exclusion criteria